Hear from CIOs, CTOs, and other C-level and senior execs on data and AI strategies at the Future of Work Summit this January 12, 2022. Learn more
InnerPulse, a North Carolina company developing treatments for abnormal heart rhythms, said it has raised $50 million in new equity financing.
The syndicate of investors included Johnson & Johnson Development Corporation, Medtronic, Inc., Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Heathcare Ventures. Additonally, Boston Scientific and Greatbatch, Inc. remain significant stockholders of InnerPulse, the company said.
From the statement:
The Company’s products employ an innovative technology to simplify the implant utilizing a minimally invasive approach that shortens the procedure, reduces post implant discomforts, and renders the device invisible. The minimally invasive nature of the technology will expand the number of implanting physicians, thereby providing access to more patients who critically need defibrillator technology.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more